Key points from article :
Israeli health-tech firm Genetika+ uses artificial intelligence (AI) software to best match antidepressants to patients, by testing them on brain cells grown from stem cells from a patient's blood sample.
"We are in the right time to be able to marry the latest computer technology and biological technology advances," says Dr Cohen Solal, Genetika+ co-founder.
Dr Heba Sailem, senior lecturer at King's College London, says that the potential for AI to transform the global pharmaceutical industry is huge.
"... senior people [in pharmaceutical companies] got to where they are by doing things the old way," explained author Calum Chace.
Alex Zhavoronkov, co-founder of Insilico Medicine, says its AI platform has reduced the time to identify potential drugs from four years to "under 18 months, for a fraction of the cost".
